REGN
REGENERON PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$814.64
+0.17%Oct 26, 2026, 11:00 UTC
Regeneron extended its agreement with BARDA to provide additional supply of Inmazeb for U.S. preparedness, adding approximately $270 million in value to the 2020 procurement agreement.
Source:Oct 25, 2026, 09:15 UTC
Longer-term follow-up data for Libtayo (cemiplimab) in high-risk cutaneous squamous cell carcinoma showed an increasing overall-survival benefit, with the reported reduction in risk of death rising from 14% to 37%; 88% of patients in the placebo arm crossed over to Libtayo upon recurrence.
Source:Oct 6, 2026, 12:03 UTC
Regeneron Pharmaceuticals agreed to dismiss its lawsuit against Sanofi over access to material information on Dupixent commercialization and audit rights under the Antibody License and Collaboration Agreement.
Oct 6, 2026, 11:00 UTC
Regeneron presented late-breaking Phase 3 C-POST data on adjuvant Libtayo (cemiplimab) for high-risk cutaneous squamous cell carcinoma after surgery and radiation at ESMO 2026.
Source:Oct 2, 2026, 17:19 UTC
Regeneron Pharmaceuticals shared clinical trial results for two investigational therapies targeting recurrent ovarian cancer and muscle loss prevention during weight management.
Source:Oct 1, 2026, 05:00 UTC
Sanofi and Regeneron expanded their longstanding antibody collaboration, adding multiple next-generation long-acting immunology antibodies including REGN20423, with Regeneron receiving $1 billion upfront and up to $7 billion in future milestones.
Sep 30, 2026, 22:04 UTC
Regeneron presented trial data showing its experimental weight-loss drug, used in combination with Novo Nordisk's semaglutide, halved muscle loss compared with semaglutide alone in patients with obesity.
Source:Sep 30, 2026, 20:24 UTC
Regeneron Pharmaceuticals granted CEO Leonard S. Schleifer and President/Chief Scientific Officer George D. Yancopoulos one-time performance share unit awards of up to 2,700,000 and 2,900,000 shares respectively, replacing annual equity awards until 2036.
Sep 28, 2026, 15:17 UTC
Regeneron Pharmaceuticals stock traded lower on Monday, likely in reaction to positive Phase 3 DAYBREAK trial data from Kodiak Sciences for wet age-related macular degeneration.
Source:Sep 24, 2026, 20:05 UTC
Regeneron Pharmaceuticals announced it will report its third quarter 2026 financial and operating results on October 30, 2026, and host a conference call and webcast that day.
Source:Sep 10, 2026, 14:45 UTC
A securities class action was filed against Bloom Energy Corporation on behalf of shareholders who purchased securities between February 27, 2025 and July 8, 2026, alleging false and misleading statements about its scandium supply chain and China exposure.
Source:Sep 10, 2026, 14:09 UTC
SueWallSt reminded shareholders of a September 29, 2026 lead plaintiff deadline in a securities class action against Pentwater Capital Management LP and its CEO over alleged manipulation of Avis Budget Group shares.
Source:Sep 1, 2026, 19:53 UTC
The Portnoy Law Firm announced a class action lawsuit against Regeneron Pharmaceuticals, Inc. on behalf of investors who bought securities between August 1, 2025 and May 15, 2026, alleging false statements during the Class Period.
Source:Aug 22, 2026, 07:10 UTC
Allworth Financial LP acquired a new position of 2,530 shares in Regeneron Pharmaceuticals, Inc. during the second quarter, as disclosed in its 13F filing.
Source:Aug 21, 2026, 08:39 UTC
A class action lawsuit was filed against Regeneron Pharmaceuticals, Inc. alleging violations of securities laws, and investors are being notified of their rights to seek lead plaintiff appointment.
Source:Aug 19, 2026, 17:02 UTC
Regeneron Pharmaceuticals' drug Pasatru for fibrodysplasia ossificans progressiva (FOP) won regulatory approval on Wednesday, August 19, 2026.
Aug 18, 2026, 07:55 UTC
BlackRock Inc. acquired a new position in Regeneron Pharmaceuticals, Inc. during the second quarter, purchasing 9,113,506 shares valued at approximately $5.68 billion, according to its 13F filing.
Source:Aug 17, 2026, 09:05 UTC
Focus Partners Advisor Solutions LLC acquired a new position in Regeneron Pharmaceuticals, Inc., purchasing 2,165 shares valued at approximately $1.35 million, as disclosed in a 13F filing.
Source:Aug 13, 2026, 00:00 UTC
Parabilis Medicines, Inc. entered into a collaboration with Regeneron, receiving $50 million upfront and a $75 million equity investment, with potential milestone payments of up to $2.2 billion.
Aug 12, 2026, 14:09 UTC
A securities class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. on behalf of shareholders who purchased securities between August 1, 2025 and May 15, 2026, alleging control-person liability related to public clinical-trial statements and SEC disclosures.
Source:Aug 11, 2026, 11:24 UTC
Zoomex launched twelve new USDT-margined stock perpetual contracts for UnitedHealth Group, General Electric, JPMorgan Chase, Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Walmart, Coca-Cola, PepsiCo, Mastercard, PayPal Holdings, and Berkshire Hathaway Class B, offering 24/7 long and short trading with up to 25x leverage.
Source:Aug 3, 2026, 11:05 UTC
Biocon announced the U.S. commercial launch of Yesafili, a biosimilar to Regeneron's Eylea 2 mg, for treating various ophthalmology conditions.
Source:Jul 30, 2026, 10:56 UTC
Regeneron Pharmaceuticals reported its Q2 FY2026 financial results, with revenue up 16.7% to $4.2907 billion and operating profit up 19.8% to $1.2935 billion.
Jun 29, 2026, 18:53 UTC
The FDA selected Eli Lilly and Regeneron among the first seven companies for its PreCheck Pilot Program to speed review of new manufacturing facilities.
Source:Jun 23, 2026, 19:26 UTC
Regeneron's applications for cemdisiran in generalized myasthenia gravis were accepted by the FDA and EMA, with FDA granting Priority Review.
Source:Jun 11, 2026, 00:00 UTC
Parabilis Medicines, Inc. signed a private placement of 4,166,666 shares of voting common stock at $18.00 per share, raising $75,000,000 from Regeneron Pharmaceuticals, Inc., concurrent with its initial public offering.
Jun 4, 2026, 18:25 UTC
Regeneron expands its partnership with CytomX to develop conditionally activated bispecific cancer therapies, with potential milestones nearing $4 billion.
Source:Jun 3, 2026, 00:00 UTC
CytomX Therapeutics amended its collaboration and license agreement with Regeneron Pharmaceuticals, extending Regeneron's program selection period and allowing up to eight new collaboration programs, with Regeneron nominating the first two programs and CytomX receiving $37.0 million in aggregate target nomination payments.
Source:Jun 1, 2026, 15:35 UTC
Regeneron Pharmaceuticals reported first-quarter earnings that exceeded analyst estimates, driven by strong sales of Dupixent and Eylea HD.
Source: